Sole-Source Supplier in Distress Requests a 22% Increase
A state agency buys 60% of its specimen collection kits from a single manufacturer. The supplier reports a 22% cost increase due to resin prices and requests a contract amendment. It has also delivered three of its last five orders late, causing clinic rescheduling. The contract is a one-year requirements contract with a 12-month renewal option, no general price-adjustment clause except for 'documented market changes,' and liquidated damages of 0.5% per week late. Qualification of an alternate supplier takes nine months and costs $150,000. The agency has 45 days of inventory. The supplier says that without relief it may exit the public-sector market. What do you do?
1. How should the agency evaluate the requested 22% increase under the contract?
Read the worked answer
The clause permits adjustment only for documented market changes. That shifts the burden to the supplier to show a relevant market movement, not merely a general claim of rising costs. Request the resin index or published price series, purchase invoices, the supplier's cost build-up, the share of resin in the kit price, and the effective date of the increase. Compare the requested 22% with the documented change; if resin is only part of the cost structure, a 22% across-the-board increase is likely overstated. Check whether the contract requires notice, negotiation, or agency approval before adjustment. Also check whether the renewal option gives the agency leverage: the agency is not obligated to renew on the same terms. Do not amend the contract based on the exit threat alone. The analysis should separate verified pass-through cost from the supplier's margin and operational problems.
2. What negotiation and supplier-management strategy fits the 45-day inventory and nine-month qualification timeline?
Read the worked answer
The agency has a short runway and no qualified alternate, so it needs a dual-track response. On the commercial track, negotiate a temporary, index-linked relief tied to documented resin costs, with a cap and a sunset date, rather than a permanent 22% increase. Require a performance improvement plan with delivery commitments, root-cause explanation for the late orders, and a schedule for rebuilding inventory. On the risk track, immediately begin qualifying a second source, even at the $150,000 cost, because a single-source dependency with a distressed supplier is an operational risk. Build a bridge inventory using expedited orders, borrow from other agencies, or extend clinic schedules only as a last resort. Use the liquidated-damages clause carefully: enforcing it may recover some money but could accelerate the supplier's exit; consider reserving the right while offering a cure period tied to improved performance. Document the tradeoff between price relief and continuity of supply.
3. Should the agency exercise the renewal option, and what contract protections should be added?
Read the worked answer
Do not automatically renew. The renewal decision should depend on verified pricing, delivery performance, and progress on a second source. If the agency renews, add protections: a price-adjustment formula limited to a specified index and cap; delivery schedules with acceptance criteria; expanded expedite and shortage remedies; a performance bond or parent-company guarantee if the supplier's financial condition warrants it; audit rights for cost data; and a termination-for-convenience or supply-interruption provision that lets the agency bridge to another source. Require the supplier to disclose financial distress and to notify the agency of any insolvency event. If performance does not improve within a defined cure period, the agency should be prepared to terminate or reduce volume and use the qualification investment already underway. The exit threat is a risk factor, not a reason to abandon the contract's protections.